

**6 January 2025**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**for**

**Edoxaban "Sandoz", film-coated tablets**

**0. D.SP.NO.**

33569

**1. NAME OF THE MEDICINAL PRODUCT**

Edoxaban "Sandoz"

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

*Edoxaban "Sandoz" 30 mg film-coated tablets*

Each film-coated tablet contains 40.412 mg edoxaban tosilate monohydrate equivalent to 30 mg edoxaban.

*Edoxaban "Sandoz" 60 mg film-coated tablets*

Each film-coated tablet contains 80.824 mg edoxaban tosilate monohydrate equivalent to 60 mg edoxaban.

Excipient(s) with known effect

*Edoxaban "Sandoz" 30 mg film-coated tablets*

Each film-coated tablet contains lactose monohydrate equivalent to 93.5 mg lactose.

*Edoxaban "Sandoz" 60 mg film-coated tablets*

Each film-coated tablet contains lactose monohydrate equivalent to 186.9 mg lactose.

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Film-coated tablets (tablets)

*Edoxaban "Sandoz" 30 mg film-coated tablets*

Light pink, round (diameter 8.6 mm), biconvex film-coated tablet debossed with “EX 30” on one side.

*Edoxaban "Sandoz" 60 mg film-coated tablets*

Light yellow, round (diameter 10.6 mm), biconvex film-coated tablet debossed with “EX 60” on one side.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Edoxaban "Sandoz" is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).

Edoxaban "Sandoz" is indicated in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).

**4.2 Posology and method of administration**

Posology

*Prevention of stroke and systemic embolism*

The recommended dose is 60 mg edoxaban once daily.

Therapy with edoxaban in NVAF patients should be continued long term.

*Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE)*

The recommended dose is 60 mg edoxaban once daily following initial use of parenteral anticoagulant for at least 5 days (see section 5.1). Edoxaban and initial parenteral anticoagulant should not be administered simultaneously.

The duration of therapy for treatment of DVT and PE (venous thromboembolism (VTE)), and prevention of recurrent VTE should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4). Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.

For NVAF and VTE the recommended dose is 30 mg edoxaban once daily in patients with one or more of the following clinical factors:

* Moderate or severe renal impairment (creatinine clearance (CrCl) 15 - 50 mL/min)
* Low body weight ≤ 60 kg
* Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole.

**Table 1: Summary of posology in NVAF and VTE (DVT and PE)**

|  |  |  |
| --- | --- | --- |
| **Summary guide for dosing** | | |
| Recommended dose |  | 60 mg edoxaban once daily |
| Dose recommendation for patients with one or more of the following clinical factors: | | |
| Renal impairment | *Moderate or severe (CrCl 15 – 50 mL/min)* | 30 mg edoxaban once daily |
| Low body weight | ≤ *60 kg* |
| P-gp inhibitors | *Ciclosporin, dronedarone, erythromycin, ketoconazole* |

*Missed dose*

If a dose of edoxaban is missed, the dose should be taken immediately and then be continued the following day with the once-daily intake as recommended. The patient should not take double the prescribed dose on the same day to make up for a missed dose.

*Switching to and from edoxaban*

Continued anticoagulant therapy is important in patients with NVAF and VTE. There may be situations that warrant a change in anticoagulation therapy (Table 2).

## Table 2: Switching of anticoagulant treatment in NVAF and VTE (DVT and PE)

|  |  |  |
| --- | --- | --- |
| **Switching to edoxaban** | | |
| **From** | **To** | **Recommendation** |
| Vitamin K antagonist (VKA) | Edoxaban | Discontinue the VKA and start edoxaban when the international normalised ratio (INR) is ≤ 2.5. |
| Oral anticoagulants other than VKA   * dabigatran * rivaroxaban * apixaban | Edoxaban | Discontinue dabigatran, rivaroxaban or apixaban and start edoxaban at the time of the next dose of the oral anticoagulant (see section 5.1). |
| Parenteral anticoagulants | Edoxaban | These medicinal products should not be administered simultaneously.  Subcutaneous anticoagulant (i.e. low molecular weight heparin (LMWH), fondaparinux):  Discontinue subcutaneous anticoagulant and start edoxaban at the time of the next scheduled subcutaneous anticoagulant dose. |
| Intravenous unfractionated heparin (UFH):  Discontinue the infusion and start edoxaban 4 hours later. |

| **Switching from edoxaban** | | |
| --- | --- | --- |
| **From** | **To** | **Recommendation** |
| Edoxaban | VKA | There is a potential for inadequate anticoagulation during the transition from edoxaban to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant.  *Oral option:* For patients currently on a 60 mg dose, administer an edoxaban dose of 30 mg once daily together with an appropriate VKA dose.  For patients currently on a 30 mg dose (for one or more of the following clinical factors: moderate to severe renal impairment (CrCl 15 – 50 mL/min), low body weight, or use with certain P-gp inhibitors), administer an edoxaban dose of 15 mg once daily together with an appropriate VKA dose.  Patients should not take a loading dose of VKA in order to promptly achieve a stable INR between 2 and 3. It is recommended to take into account the maintenance dose of VKA and if the patient was previously taking a VKA or to use valid INR driven VKA treatment algorithm, in accordance with local practice.  Once an INR ≥ 2.0 is achieved, edoxaban should be discontinued. Most patients (85%) should be able to achieve an INR ≥ 2.0 within 14 days of concomitant administration of edoxaban and VKA. After 14 days it is recommended that edoxaban is discontinued and the VKA continued to be titrated to achieve an INR between 2 and 3.  It is recommended that during the first 14 days of concomitant therapy the INR is measured at least 3 times just prior to taking the daily dose of edoxaban to minimise the influence of edoxaban on INR measurements. Concomitant edoxaban and VKA can increase the INR post edoxaban dose by up to 46%.  *Parenteral option:* Discontinue edoxaban and administer a parenteral anticoagulant and VKA at the time of the next scheduled edoxaban dose. Once a stable INR of ≥ 2.0 is achieved, the parenteral  anticoagulant should be discontinued and the VKA continued. |
| Edoxaban | Oral anticoagulants other than VKA | Discontinue edoxaban and start the non-VKA  anticoagulant at the time of the next scheduled dose of edoxaban. |
| Edoxaban | Parenteral anticoagulants | These medicinal products should not be administered simultaneously. Discontinue edoxaban and start the parenteral anticoagulant at the time of the next scheduled dose of edoxaban. |

Special populations

*Elderly population*

No dose reduction is required (see section 5.2).

*Renal impairment*

Renal function should be assessed in all patients by calculating the CrCl prior to initiation of treatment with edoxaban to exclude patients with end stage renal disease (i.e. CrCl < 15 mL/min), to use the correct edoxaban dose in patients with CrCl 15 – 50 mL/min (30 mg once daily), in patients with CrCl > 50 mL/min (60 mg once daily) and when deciding on the use of edoxaban in patients with increased CrCl (see section 4.4).

Renal function should also be assessed when a change in renal function is suspected during treatment (e.g. hypovolaemia, dehydration, and in case of concomitant use of certain medicinal products).

The method used to estimate renal function (CrCl in mL/min) during the clinical development of edoxaban was the Cockcroft-Gault method. The formula is as follows:

* For creatinine in µmol/L:

1.23 × (140-age [years]) × weight [kg] (× 0.85 if female)

serum creatinine [µmol/L]

* For creatinine in mg/dL:

(140-age [years]) × weight [kg] (× 0.85 if female)

72 × serum creatinine [mg/dL]

This method is recommended when assessing patients’ CrCl prior to and during edoxaban treatment.

In patients with mild renal impairment (CrCl > 50 – 80 mL/min), the recommended dose is 60 mg edoxaban once daily.

In patients with moderate or severe renal impairment (CrCl 15 – 50 mL/min), the recommended dose is 30 mg edoxaban once daily (see section 5.2).

In patients with end stage renal disease (ESRD) (CrCl < 15 mL/min) or on dialysis, the use of edoxaban is not recommended (see sections 4.4 and 5.2).

*Hepatic impairment*

Edoxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).

In patients with severe hepatic impairment edoxaban is not recommended (see sections 4.4 and 5.2).

In patients with mild to moderate hepatic impairment the recommended dose is 60 mg edoxaban once daily (see section 5.2). Edoxaban should be used with caution in patients with mild to moderate hepatic impairment (see section 4.4).

Patients with elevated liver enzymes (alanine aminotransferase (ALT) or aspartate transaminase (AST) > 2 x upper limit of normal (ULN)) or total bilirubin ≥ 1.5 x ULN, were excluded in clinical studies. Therefore edoxaban should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating edoxaban, liver function testing should be performed.

*Body weight*

For patients with body weight ≤ 60 kg, the recommended dose is 30 mg edoxaban once daily (see section 5.2).

*Gender*

No dose reduction is required (see section 5.2).

*Concomitant use of Edoxaban "Sandoz" with P-glycoprotein (P-gp) inhibitors*

In patients concomitantly taking Edoxaban "Sandoz" and the following P-gp inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole, the recommended dose is 30 mg Edoxaban "Sandoz" once daily (see section 4.5). No dose reduction is required for concomitant use of amiodarone, quinidine or verapamil (see section 4.5).

The use of Edoxaban "Sandoz" with other P-gp inhibitors including HIV protease inhibitors has not been studied.

*Patients undergoing cardioversion*

Edoxaban "Sandoz" can be initiated or continued in patients who may require cardioversion. For transoesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Edoxaban "Sandoz" treatment should be started at least **2 hours** before cardioversion to ensure adequate anticoagulation (see sections 5.1 and 5.2). Cardioversion should be performed no later than 12 hours after the dose of Edoxaban "Sandoz" on the day of the procedure.

**For all patients undergoing cardioversion:** Confirmation should be sought prior to cardioversion that the patient has taken Edoxaban "Sandoz" as prescribed. Decisions on initiation and duration of treatment should follow established guidelines for anticoagulant treatment in patients undergoing cardioversion.

*Paediatric population*

Edoxaban is not recommended for use in children and adolescents from birth to 18 years of age with confirmed VTE (PE and/or DVT) event as the efficacy has not been established. Available data in VTE patients are described in sections 4.8, 5.1 and 5.2.

Method of administration

For oral use.

Edoxaban can be taken with or without food (see section 5.2).

For patients who are unable to swallow whole tablets, Edoxaban "Sandoz" tablets may be crushed and mixed with water or apple puree and immediately administered orally (see section 5.2).

Alternatively, Edoxaban "Sandoz" tablets may be crushed and suspended in a small amount of water and immediately delivered through a nasogastric tube or gastric feeding tube after which it should be flushed with water (see section 5.2). Crushed Edoxaban "Sandoz" tablets are stable in water and apple puree for up to 4 hours.

For further information on administration through gastric feeding tube, see section 6.6.

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Clinically significant active bleeding.

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Uncontrolled severe hypertension.

Concomitant treatment with any other anticoagulants e.g. UFH, LMWH (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, rivaroxaban, apixaban etc.) except under specific circumstances of switching oral anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Pregnancy and breast-feeding (see section 4.6).

**4.4 Special warnings and precautions for use**

Edoxaban 15 mg is not indicated as monotherapy, as it may result in decreased efficacy. It is only indicated in the process of switching from edoxaban 30 mg (patients with one or more clinical factors for increased exposure; see table 1) to VKA, together with an appropriate VKA dose (see table 2, section 4.2).

Haemorrhagic risk

Edoxaban increases the risk of bleeding and can cause serious, potentially fatal bleeding. Edoxaban, like other anticoagulants, is recommended to be used with caution in patients with increased risk of bleeding. Edoxaban administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9).

In the clinical studies mucosal bleedings (e.g. epistaxis, gastrointestinal, genitourinary) and anaemia were seen more frequently during long term edoxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding, as judged to be appropriate.

Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8). Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.

The anticoagulant effect of edoxaban cannot be reliably monitored with standard laboratory testing. A specific anticoagulant reversal agent for edoxaban is not available (see section 4.9).

Haemodialysis does not significantly contribute to edoxaban clearance (see section 5.2).

Elderly

The co-administration of edoxaban with acetylsalicylic acid (ASA) in elderly patients should be used cautiously because of a potentially higher bleeding risk (see section 4.5).

Renal impairment

The plasma area under the curve (AUC) for subjects with mild (CrCl > 50 - 80 mL/min), moderate (CrCl 30 - 50 mL/min) and severe (CrCl < 30 mL/min but not undergoing dialysis) renal impairment was increased by 32%, 74%, and 72%, respectively, relative to subjects with normal renal function (see section 4.2 for dose reduction).

In patients with end stage renal disease or on dialysis, Edoxaban "Sandoz" is not recommended (see sections 4.2 and 5.2).

*Renal function in NVAF*

A trend towards decreasing efficacy with increasing CrCl was observed for edoxaban compared to well-managed warfarin (see section 5.1 for ENGAGE AF-TIMI 48 and additional data from E314 and ETNA-AF).

Edoxaban should be used in patients with NVAF and high CrCl only after a careful evaluation of the individual thromboembolic and bleeding risk.

Assessment of renal function: CrCl should be monitored at the beginning of the treatment in all patients and afterwards when clinically indicated (see section 4.2).

Hepatic impairment

Edoxaban is not recommended in patients with severe hepatic impairment (see sections 4.2 and 5.2).

Edoxaban should be used with caution in patients with mild or moderate hepatic impairment (see section 4.2).

Patients with elevated liver enzymes (ALT/AST > 2 x ULN) or total bilirubin ≥ 1.5 x ULN were excluded in clinical studies. Therefore edoxaban should be used with caution in this population (see sections 4.2 and 5.2). Prior to initiating edoxaban, liver function testing should be performed.

Periodic hepatic monitoring is recommended for patients on edoxaban treatment beyond 1 year.

Discontinuation for surgery and other interventions

If anticoagulation must be discontinued to reduce the risk of bleeding with surgical or other procedures, edoxaban should be stopped as soon as possible and preferably at least 24 hours before the procedure.

In deciding whether a procedure should be delayed until 24 hours after the last dose of edoxaban, the increased risk of bleeding should be weighed against the urgency of the intervention. Edoxaban should be restarted after the surgical or other procedures as soon as adequate haemostasis has been established, noting that the time to onset of the edoxaban anticoagulant therapeutic effect is 1 – 2 hours. If oral medicinal products cannot be taken during or after surgical intervention, consider administering a parenteral anticoagulant and then switch to oral once daily edoxaban (see section 4.2).

Interaction with other medicinal products affecting haemostasis

Concomitant use of medicines affecting haemostasis may increase the risk of bleeding. These include ASA, P2Y12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), and chronic nonsteroidal anti-inflammatory drugs (NSAIDs) (see section 4.5).

Prosthetic heart valves and moderate to severe mitral stenosis

Edoxaban has not been studied in patients with mechanical heart valves, in patients during the first 3 months after implantation of a bioprosthetic heart valve, with or without atrial fibrillation, or in patients with moderate to severe mitral stenosis. Therefore, use of edoxaban is not recommended in these patients.

Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy

Edoxaban is not recommended as an alternative to UFH in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of edoxaban have not been established in these clinical situations.

Patients with active cancer

Efficacy and safety of edoxaban in the treatment and/or prevention of VTE in patients with active cancer have not been established.

Patients with antiphospholipid syndrome

Direct acting oral anticoagulants (DOACs) including edoxaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

Laboratory coagulation parameters

Although treatment with edoxaban does not require routine monitoring, the effect on anticoagulation can be estimated by a calibrated quantitative anti-Factor Xa (anti-FXa) assay which may help to inform clinical decisions in particular situations as, e.g. overdose and emergency surgery (see also section 5.2).

Edoxaban prolongs standard clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT) as a result of Factor Xa (FXa) inhibition. Changes observed in these clotting tests at the expected therapeutic dose are, however, small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of edoxaban.

Edoxaban "Sandoz" contains lactose

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicine.

Edoxaban "Sandoz" contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

**4.5 Interaction with other medicinal products and other forms of interaction**

Edoxaban is predominantly absorbed in the upper gastrointestinal (GI) tract. Thus, medicinal products or disease conditions that increase gastric emptying and gut motility have the possibility of reducing edoxaban dissolution and absorption.

P-gp inhibitors

Edoxaban is a substrate for the efflux transporter P-gp. In pharmacokinetic (PK) studies, concomitant administration of edoxaban with the P-gp inhibitors ciclosporin, dronedarone, erythromycin, ketoconazole, quinidine, or verapamil resulted in increased plasma concentrations of edoxaban.

Concomitant use of edoxaban with ciclosporin, dronedarone, erythromycin, or ketoconazole requires dose reduction to 30 mg once daily. Concomitant use of edoxaban with quinidine, verapamil, or amiodarone does not require dose reduction based on clinical data (see section 4.2).

The use of edoxaban with other P-gp inhibitors including human immunodeficiency virus (HIV) protease inhibitors has not been studied.

Edoxaban 30 mg once daily must be administered during concomitant use with the following P-gp inhibitors:

* *Ciclosporin:* Concurrent administration of a single dose of ciclosporin 500 mg with a single dose of edoxaban 60 mg increased edoxaban AUC and maximum serum concentration (Cmax) by 73% and 74%, respectively.
* *Dronedarone:* Dronedarone 400 mg twice daily for 7 days with a single concomitant dose of edoxaban 60 mg on day 5 increased edoxaban AUC and Cmax by 85% and 46%, respectively.
* *Erythromycin:* Erythromycin 500 mg four times daily for 8 days with a single concomitant dose of edoxaban 60 mg on day 7 increased the edoxaban AUC and Cmax by 85% and 68%, respectively.
* *Ketoconazole:* Ketoconazole 400 mg once daily for 7 days with a single concomitant dose of edoxaban 60 mg on day 4, increased edoxaban AUC and Cmax by 87% and 89%, respectively.

Edoxaban 60 mg once daily is recommended during concomitant use with the following P-gp inhibitors:

* *Quinidine:* Quinidine 300 mg once daily on days 1 and 4 and three times daily on days 2 and 3, with a single concomitant dose of edoxaban 60 mg on day 3, increased edoxaban AUC over 24 hours by 77% and Cmax by 85%, respectively.
* *Verapamil:* Verapamil 240 mg once daily for 11 days with a single concomitant dose of edoxaban 60 mg on day 10 increased the edoxaban AUC and Cmax by approximately 53%.
* *Amiodarone:* Co-administration of amiodarone 400 mg once daily with edoxaban 60 mg once daily increased AUC by 40% and Cmax by 66%. This was not considered clinically significant. In ENGAGE AF-TIMI 48 study in NVAF, efficacy and safety results were similar for subjects with and without concomitant amiodarone use.
* *Clarithromycin:* Clarithromycin (500 mg twice daily) for 10 days with a single concomitant dose of edoxaban 60 mg on day 9 increased the edoxaban AUC and Cmax by approximately 53% and 27%, respectively.

P-gp inducers

Co-administration of edoxaban with the P-gp inducer rifampicin led to a decrease in mean edoxaban AUC and a shortened half-life, with possible decreases in its pharmacodynamic effects. The concomitant use of edoxaban with other P-gp inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John's Wort) may lead to reduced edoxaban plasma concentrations. Edoxaban should be used with caution when co-administered with P-gp inducers.

P-gp substrates

*Digoxin*

Edoxaban 60 mg once daily on days 1 to 14 with coadministration of multiple daily doses of digoxin 0.25 mg twice daily (days 8 and 9) and 0.25 mg once daily (days 10 to 14) increased the Cmax of edoxaban by 17%, with no significant effect on AUC or renal clearance at steady state. When the effects of edoxaban on digoxin PK were also examined, the Cmax of digoxin increased by approximately 28% and AUC by 7%. This was not considered clinically relevant. No dose modification is necessary when edoxaban is administered with digoxin.

Anticoagulants, antiplatelets, NSAIDs and SSRIs/SNRIs

*Anticoagulants*

Co-administration of edoxaban with other anticoagulants is contraindicated due to increased risk of bleeding (see section 4.3).

*ASA*

Co-administration of ASA (100 mg or 325 mg) and edoxaban increased bleeding time relative to either medicinal product alone. Co-administration of high dose ASA (325 mg) increased the steady state Cmax and AUC of edoxaban by 35% and 32%, respectively. The concomitant chronic use of high dose ASA (325 mg) with edoxaban is not recommended. Concomitant administration of higher doses than 100 mg ASA should only be performed under medical supervision.

In clinical studies concomitant use of ASA (low dose ≤ 100 mg/day), other antiplatelet agents, and thienopyridines was permitted and resulted in approximately a 2-fold increase in major bleeding in comparison with no concomitant use, although to a similar extent in the edoxaban and warfarin groups (see section 4.4). Co-administration of low dose ASA (≤ 100 mg) did not affect the peak or total exposure of edoxaban either after single dose or at steady-state.

Edoxaban can be co-administered with low dose ASA (≤ 100 mg/day).

*Platelet inhibitors*

In ENGAGE AF-TIMI 48 concomitant use of thienopyridines (e.g. clopidogrel) monotherapy was permitted and resulted in increased clinically relevant bleeding although with a lower risk of bleeding on edoxaban compared to warfarin (see section 4.4).

There is very limited experience on the use of edoxaban with dual antiplatelet therapy or fibrinolytic agents.

*NSAIDs*

Co-administration of naproxen and edoxaban increased bleeding time relative to either medicinal product alone. Naproxen had no effect on the Cmax and AUC of edoxaban. In clinical studies, co-administration of NSAIDs resulted in increased clinically relevant bleeding. Chronic use of NSAIDs with edoxaban is not recommended.

*SSRIs/SNRIs*

As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets (see section 4.4).

Effect of edoxaban on other medicinal products

Edoxaban increased the Cmax of concomitantly administered digoxin by 28%; however, the AUC was not affected. Edoxaban had no effect on the Cmax and AUC of quinidine.

Edoxaban decreased the Cmax and AUC of concomitantly administered verapamil by 14% and 16%, respectively.

**4.6 Fertility, pregnancy and lactation**

Women of childbearing potential

Women of childbearing potential should avoid becoming pregnant during treatment with edoxaban.

Pregnancy

Safety and efficacy of edoxaban have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that edoxaban passes the placenta, Edoxaban "Sandoz" is contraindicated during pregnancy (see section 4.3).

Breast-feeding

Safety and efficacy of edoxaban have not been established in breast-feeding women. Data from animals indicate that edoxaban is secreted into breast milk. Therefore Edoxaban "Sandoz" is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from therapy.

Fertility

No specific studies with edoxaban in human beings have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).

**4.7 Effects on ability to drive and use machines**

No traffic warning.

Edoxaban "Sandoz" has no or negligible influence on the ability to drive and use machines.

**4.8 Undesirable effects**

Summary of the safety profile

The safety profile of edoxaban is based on two Phase 3 studies (21,105 patients with NVAF and 8,292 patients with VTE (DVT and PE)), and from post-authorisation experience.

The most commonly reported adverse reactions associated with edoxaban treatment are epistaxis (7.7%), haematuria (6.9%) and anaemia (5.3%).

Bleeding can occur at any site and may be severe and even fatal (see section 4.4).

Tabulated list of adverse reactions

Table 3 provides the list of adverse reactions from the two pivotal Phase 3 studies in patients with VTE and NVAF combined for both indications and adverse drug reactions identified in the post- marketing setting. The adverse reactions are classified according to the MedDRA system organ class (SOC) and frequency, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

## Table 3: List of adverse reactions for NVAF and VTE

| **System organ class** | **Frequency** |
| --- | --- |
| **Blood and lymphatic system disorders** |  |
| Anaemia | Common |
| Thrombocytopenia | Uncommon |
| **Immune system disorders** |  |
| Hypersensitivity | Uncommon |
| Anaphylactic reaction | Rare |
| Allergic oedema | Rare |
| **Nervous system disorders** |  |
| Dizziness | Common |
| Headache | Common |
| Intracranial haemorrhage (ICH) | Uncommon |
| Subarachnoid haemorrhage | Rare |
| **Eye disorders** |  |
| Conjunctival/scleral haemorrhage | Uncommon |
| Intraocular haemorrhage | Uncommon |
| **Cardiac disorders** |  |
| Pericardial haemorrhage | Rare |
| **Vascular disorders** |  |
| Other haemorrhage | Uncommon |
| **Respiratory, thoracic and mediastinal disorders** |  |
| Epistaxis | Common |
| Haemoptysis | Uncommon |
| **Gastrointestinal disorders** |  |
| Abdominal pain | Common |
| Lower GI haemorrhage | Common |
| Upper GI haemorrhage | Common |
| Oral/pharyngeal haemorrhage | Common |
| Nausea | Common |
| Retroperitoneal haemorrhage | Rare |
| **Hepatobiliary disorders** |  |
| Blood bilirubin increased | Common |
| Gammaglutamyltransferase increased | Common |
| Blood alkaline phosphatase increased | Uncommon |
| Transaminases increased | Uncommon |
| **Skin and subcutaneous tissue disorders** |  |
| Cutaneous soft tissue haemorrhage | Common |
| Rash | Common |
| Pruritus | Common |
| Urticaria | Uncommon |
| **Musculoskeletal and connective tissue disorders** |  |
| Intramuscular haemorrhage (no compartment syndrome) | Rare |
| Intra-articular haemorrhage | Rare |
| **Renal and urinary disorders** |  |
| Macroscopic haematuria/urethral haemorrhage | Common |
| Anticoagulant-related nephropathy | Not known |
| **Reproductive system and breast disorders** |  |
| Vaginal haemorrhage1 | Common |
| **General disorders and administration site conditions** |  |
| Puncture site haemorrhage | Common |
| **Investigations** |  |
| Liver function test abnormal | Common |
| **Injury, poisoning and procedural complications** |  |
| Surgical site haemorrhage | Uncommon |
| Subdural haemorrhage | Rare |
| Procedural haemorrhage | Rare |

1 Reporting rates are based on the female population in clinical studies. Vaginal bleeds were reported commonly in women under the age of 50 years, while it was uncommon in women over the age of 50 years.

Description of selected adverse reactions

*Haemorrhagic anaemia*

Due to the pharmacological mode of action, the use of edoxaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9). In the clinical studies mucosal bleedings (e.g. epistaxis, gastrointestinal, genitourinary) and anaemia were seen more frequently during long term edoxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea, and unexplained shock.

Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion, or anticoagulant-related nephropathy have been reported for edoxaban. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.

Paediatric population

The safety of edoxaban was evaluated in two Phase 3 studies (Hokusai VTE PEDIATRICS and ENNOBLE-ATE) in paediatric patients from birth to less than 18 years of age with VTE (286 patients, 145 patients treated with edoxaban) and cardiac diseases at risk of thrombotic events (167 patients, 109 patients treated with edoxaban). Overall, the safety profile in children was similar as in the adult patient population (see Table 3). In total, 16.6% of paediatric patients treated with edoxaban for VTE experienced adverse reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Lægemiddelstyrelsen

Axel Heides Gade 1

DK-2300 København S

Website: www.meldenbivirkning.dk

**4.9 Overdose**

Overdose with edoxaban may lead to haemorrhage. Experience with overdose cases is very limited.

A specific antidote antagonising the pharmacodynamic effect of edoxaban is not available.

Early administration of activated charcoal may be considered in case of edoxaban overdose to reduce absorption. This recommendation is based on standard treatment of medicinal product overdose and data available with similar compounds, as the use of activated charcoal to reduce absorption of edoxaban has not been specifically studied in the edoxaban clinical programme.

Management of bleeding

Should a bleeding complication arise in a patient receiving edoxaban, the next edoxaban administration should be delayed or treatment should be discontinued as appropriate. Edoxaban has a half-life of approximately 10 to 14 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.

For life-threatening bleeding that cannot be controlled with the measures such as transfusion or haemostasis, the administration of a 4-factor prothrombin complex concentrate (PCC) at 50 IU/kg has been shown to reverse the effects of edoxaban 30 minutes after completing the infusion.

Recombinant factor VIIa (r-FVIIa) can also be considered. However, there is limited clinical experience with the use of this product in individuals receiving edoxaban.

Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings.

Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of edoxaban.

There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving edoxaban. There is neither scientific rationale for benefit nor experience with the use of systemic haemostatics (desmopressin, aprotinin) in individuals receiving edoxaban. Due to the high plasma protein binding edoxaban is not expected to be dialysable.

**4.10 Legal status**

B

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors; ATC code: B01AF03

Mechanism of action

Edoxaban is a highly selective, direct and reversible inhibitor of FXa, the serine protease located in the final common pathway of the coagulation cascade. Edoxaban inhibits free FXa, and prothrombinase activity. Inhibition of FXa in the coagulation cascade reduces thrombin generation, prolongs clotting time and reduces the risk of thrombus formation.

Pharmacodynamic effects

Edoxaban produces rapid onset of pharmacodynamic effects within 1 - 2 hours, which corresponds with peak edoxaban exposure (Cmax). The pharmacodynamic effects measured by anti-FXa assay are predictable and correlate with the dose and the concentration of edoxaban. As a result of FXa inhibition, edoxaban also prolongs clotting time in tests such as PT, and aPTT. Changes observed in these clotting tests are expected at the therapeutic dose, however, these changes are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of edoxaban.

*Effects of coagulation markers when switching from rivaroxaban, dabigatran, or apixaban to edoxaban*

In clinical pharmacology studies, healthy subjects received rivaroxaban 20 mg once daily, dabigatran 150 mg twice daily, or apixaban 5 mg twice daily, followed by a single dose of edoxaban 60 mg on day 4. The effect on PT and other coagulation biomarkers (e.g. anti-FXa, aPTT) was measured.

Following the switch to edoxaban on day 4 the PT was equivalent to day 3 of rivaroxaban and apixaban. For dabigatran higher aPTT activity was observed after edoxaban administration with prior dabigatran treatment compared to that after treatment with edoxaban alone. This is considered to be due to the carry-over effect of dabigatran treatment, however, this did not lead to a prolongation of bleeding time.

Based on these data, when switching from these anticoagulants to edoxaban, the first dose of edoxaban can be initiated at the time of the next scheduled dose of the previous anticoagulant (see section 4.2).

Clinical efficacy and safety

*Prevention of stroke and systemic embolism*

The edoxaban clinical programme for atrial fibrillation was designed to demonstrate the efficacy and safety of two dose groups of edoxaban compared to warfarin for the prevention of stroke and systemic embolism in subjects with NVAF and at moderate to high risk of stroke and systemic embolic events (SEE).

In the pivotal ENGAGE AF-TIMI 48 study (an event-driven, Phase 3, multi-centre, randomised, double-blind double-dummy parallel-group study), 21,105 subjects, with a mean congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke (CHADS2) score of 2.8, were randomised to either edoxaban 30 mg once daily treatment group, or edoxaban 60 mg once daily treatment group or warfarin. Subjects in both edoxaban treatment groups had their dose halved if one or more of the following clinical factors were present: moderate renal impairment (CrCl 30 – 50 mL/min), low body weight (≤ 60 kg) or concomitant use of specific P-gp inhibitors (verapamil, quinidine, dronedarone).

The primary efficacy endpoint was the composite of stroke and SEE. Secondary efficacy endpoints included: composite of stroke, SEE, and cardiovascular (CV) mortality; major adverse cardiovascular event (MACE), which is the composite of non-fatal myocardial infarction (MI), non-fatal stroke, non- fatal SEE, and death due to CV cause or bleeding; composite of stroke, SEE, and all-cause mortality.

The median study medicinal product exposure for both the edoxaban 60 mg and 30 mg treatment groups was 2.5 years. The median study follow-up for both the edoxaban 60 mg and 30 mg treatment groups was 2.8 years. The median subject-year exposure was 15,471, and 15,840 for the 60 mg and 30 mg treatment groups, respectively; and the median subject-year follow-up was 19,191 and 19,216 for the 60 mg and 30 mg treatment groups, respectively.

In the warfarin group, the median TTR (time in therapeutic range, INR 2.0 to 3.0) was 68.4%.

The main analysis of efficacy was aimed to show the non-inferiority of edoxaban versus warfarin on first stroke or SEE that occurred during treatment or within 3 days from the last dose taken in the modified intention to treat (mITT) population. Edoxaban 60 mg was non-inferior to warfarin for the primary efficacy endpoint of stroke or SEE (upper limit of the 97.5% CI of the hazard ratio (HR) was below the pre-specified non-inferiority margin of 1.38) (Table 4).

## Table 4: Strokes and SEE in the ENGAGE AF–TIMI 48 study - mITT, on-treatment

|  |  |  |
| --- | --- | --- |
| **Primary endpoint** | **Edoxaban 60 mg (30 mg dose reduced)**  **(N = 7,012)** | **Warfarin**  **(N = 7,012)** |
| **First stroke/SEE**a |  |  |
| n | 182 | 232 |
| Event rate (%/yr)b | 1.18 | 1.50 |
| HR (97.5% CI) | 0.79 (0.63, 0.99) |  |
| p-value for non-inferiorityc | <0.0001 |  |
| **First ischaemic stroke** |  |  |
| n | 135 | 144 |
| Event rate (%/yr)b | 0.87 | 0.93 |
| HR (95% CI) | 0.94 (0.75, 1.19) |  |
| **First haemorrhagic stroke** |  |  |
| n | 40 | 76 |
| Event rate (%/yr)b | 0.26 | 0.49 |
| HR (95% CI) | 0.53 (0.36, 0.78) |  |
| **First SEE** |  |  |
| n (%/yr)a | 8 (0.05) | 13 (0.08) |
| HR (95% CI) | 0.62 (0.26, 1.50) |  |

Abbreviations: HR = hazard ratio versus warfarin, CI = confidence interval, n = number of events, mITT = modified intent to treat, N = number of subjects in mITT population,

SEE = systemic embolic event, yr = year.

a A subject can be represented in multiple rows.

b The event rate (%/yr) is calculated as number of events/subject-year exposure.

c The two-sided p-value is based on the non-inferiority margin of 1.38.

During the overall study period in the ITT population (analysis set to show superiority), adjudicated stroke or SEE occurred in 296 subjects in the edoxaban 60 mg group (1.57% per year), and 337 subjects in the warfarin group (1.80% per year). Compared to warfarin-treated subjects, the HR in the edoxaban 60 mg group was 0.87 (99% CI: 0.71, 1.07, p = 0.08 for superiority).

In subgroup analyses, for subjects in the 60 mg treatment group who were dose reduced to 30 mg in the ENGAGE AF-TIMI 48 study (for body weight ≤ 60 kg, moderate renal impairment, or concomitant use of P-gp inhibitors), the event rate was: 2.29% per year for the primary endpoint, compared to the event rate of 2.66% per year for the matching subjects in the warfarin group [HR (95% CI): 0.86 (0.66, 1.13)].

The efficacy results for pre-specified major subgroups (with dose reduction as required), including age, body weight, gender, status of renal function, prior stroke or TIA, diabetes and P-gp inhibitors were generally consistent with the primary efficacy results for the overall population studied in the trial.

The HR (edoxaban 60 mg vs. warfarin) for the primary endpoint in the centres with a lower average time of INR in the therapeutic range (INR TTR) for warfarin was 0.73 – 0.80 for the lowest 3 quartiles (INR TTR ≤ 57.7% to ≤ 73.9%). It was 1.07 in centres with the best control of warfarin therapy (4th quartile with > 73.9% of INR values in the therapeutic range).

There was a statistically significant interaction between the effect of edoxaban versus warfarin on the main study outcome (stroke/SEE) and renal function (p-value 0.0042; mITT, overall study period).

Table 5 shows ischaemic strokes/SEE by CrCl category in NVAF patients in ENGAGE AF-TIMI 48. There is a decreasing event rate at increasing CrCl in both treatment groups.

**Table 5: Number of ischaemic strokes/SEE by CrCl category in the ENGAGE AF-TIMI 48, mITT analysis set overall study**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **CrCl subgroup (mL/min)** | **Edoxaban 60 mg**  **(N = 7,012)** | | | **Warfarin (N = 7,012)** | | |  |
| **n** | **Number of events** | **Event rate**  **(%/year)** | **n** | **Number of events** | **Event rate (%/year)** | **HR (95% CI)** |
| ≥ 30 to ≤ 50 | 1,302 | 63 | 1.89 | 1,305 | 67 | 2.05 | 0.93 (0.66, 1.31) |
| > 50 to ≤ 70 | 2,093 | 85 | 1.51 | 2,106 | 95 | 1.70 | 0.88 (0.66, 1.18) |
| > 70 to ≤ 90 | 1,661 | 45 | 0.99 | 1,703 | 50 | 1.08 | 0.92 (0.61, 1.37) |
| > 90 to ≤ 110 | 927 | 27 | 1.08 | 960 | 26 | 0.98 | 1.10 (0.64, 1.89) |
| > 110 to ≤ 130 | 497 | 14 | 1.01 | 469 | 10 | 0.78 | 1.27 (0.57, 2.85) |
| > 130 | 462 | 10 | 0.78 | 418 | 3 | 0.25 | --\* |

Abbreviations: CrCl = creatinine clearance; N = number of subjects in mITT population overall study period; mITT = modified intent to treat; n = number of patients in subgroup; HR = hazard ratio versus warfarin; CI = confidence interval.

\*HR not computed if number of events < 5 in one treatment group.

Within renal function subgroups, results for the secondary efficacy endpoints were consistent with those for the primary endpoint.

Superiority testing was performed on the ITT overall study period.

Stroke and SEE occurred in fewer subjects in the edoxaban 60 mg treatment group than in the warfarin group (1.57% and 1.80% per year, respectively), with a HR of 0.87 (99% CI: 0.71, 1.07, p = 0.0807 for superiority).

The pre-specified composite endpoints for the comparison of the edoxaban 60 mg treatment group to warfarin for stroke, SEE, and CV mortality HR (99% CI) was 0.87 (0.76, 0.99), MACE 0.89 (0.78, 1.00), and stroke, SEE, and all-cause mortality 0.90 (0.80, 1.01).

The results for all-cause mortality (adjudicated deaths) in the ENGAGE AF-TIMI 48 study were 769 (3.99% per year) for subjects taking edoxaban 60 mg (30 mg dose reduced) as opposed to 836 (4.35% per year) for warfarin [HR (95% CI): 0.91 (0.83, 1.01)].

All-cause mortality (adjudicated deaths) per renal subgroups (edoxaban vs. warfarin): CrCl 30 to ≤ 50 mL/min [HR (95% CI): 0.81 (0.68, 0.97)]; CrCl > 50 to < 80 mL/min [HR (95% CI): 0.87 (0.75, 1.02)]; CrCl ≥ 80 mL/min [HR (95% CI): 1.15 (0.95, 1.40)].

Edoxaban 60 mg (30 mg dose reduced) resulted in a lower rate of cardiovascular mortality compared to warfarin [HR (95% CI): 0.86 (0.77, 0.97)].

Adjudicated efficacy cardiovascular mortality per renal subgroups (edoxaban vs. warfarin): CrCl 30 to ≤ 50 mL/min [HR (95% CI): 0.80 (0.65, 0.99)]; CrCl > 50 to < 80 mL/min [HR (95% CI): 0.75 (0.62, 0.90)]; CrCl ≥ 80 mL/min [HR (95% CI): 1.16 (0.92, 1.46)].

The primary safety endpoint was major bleeding.

There was a significant risk reduction in the edoxaban 60 mg treatment group compared with the warfarin group in major bleeding (2.75%, and 3.43% per year, respectively) [HR (95% CI): 0.80 (0.71, 0.91); p = 0.0009], ICH (0.39%, and 0.85% per year, respectively) [HR (95% CI): 0.47 (0.34, 0.63); p < 0.0001], and other types of bleeding (Table 6).

The reduction in fatal bleeds was also significant for the edoxaban 60 mg treatment group compared with the warfarin group (0.21%, and 0.38%) [HR (95% CI): 0.55 (0.36, 0.84); p = 0.0059 for superiority], primarily because of the reduction in fatal ICH bleeds [HR (95% CI): 0.58 (0.35, 0.95); p = 0.0312].

## Table 6: Bleeding events in ENGAGE AF-TIMI 48 study - safety analysis on-treatment

|  |  |  |
| --- | --- | --- |
|  | **Edoxaban 60 mg (30 mg dose reduced)**  **(N = 7,012)** | **Warfarin**  **(N = 7,012)** |
| **Major bleeding** |  |  |
| n | 418 | 524 |
| Event rate (%/yr)a | 2.75 | 3.43 |
| HR (95% CI) | 0.80 (0.71, 0.91) |  |
| p-value | 0.0009 |  |
| ICHb |  |  |
| n | 61 | 132 |
| Event rate (%/yr)a | 0.39 | 0.85 |
| HR (95% CI) | 0.47 (0.34, 0.63) |  |
| **Fatal bleeding** |  |  |
| n | 32 | 59 |
| Event rate (%/yr)a | 0.21 | 0.38 |
| HR (95% CI) | 0.55 (0.36, 0.84) |  |
| **CRNM Bleeding** |  |  |
| n | 1,214 | 1,396 |
| Event rate (%/yr)a | 8.67 | 10.15 |
| HR (95% CI) | 0.86 (0.80, 0.93) |  |
| **Any confirmed bleedingc** |  |  |
| n | 1,865 | 2,114 |
| Event rate (%/yr)a | 14.15 | 16.40 |
| HR (95% CI) | 0.87 (0.82, 0.92) |  |

Abbreviations: ICH = intracranial haemorrhage, HR = hazard ratio versus warfarin,

CI = confidence interval, CRNM = clinically relevant non-major, n = number of subjects with events, N = number of subjects in safety population, yr = year.

a The event rate (%/yr) is calculated as number of events/subject-year exposure.

b ICH includes primary haemorrhagic stroke, subarachnoid haemorrhage, epi-/subdural haemorrhage, and ischaemic stroke with major haemorrhagic conversion. All ICHs reported on the adjudicated cerebrovascular and non-intracranial bleed electronic case report forms (eCRF) confirmed by the adjudicators are included in ICH counts.

c 'Any confirmed bleeding includes those that the adjudicator defined as clinically overt.

Note: A subject can be included in multiple sub-categories if he/she had an event for those categories. The first event of each category is included in the analysis.

Tables 7, 8 and 9 show major, fatal and intracranial bleedings, respectively, by CrCl category in NVAF patients in ENGAGE AF-TIMI 48. There is a decreasing event rate at increasing CrCl in both treatment groups.

**Table 7: Number of major bleeding events by CrCl category in ENGAGE AF-TIMI 48, safety analysis on-treatmenta**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **CrCl subgroup (mL/min)** | **Edoxaban 60 mg**  **(N = 7,012)** | | | **Warfarin**  **(N = 7,012)** | | |  |
| **n** | **Number of events** | **Event rate**  **(%/year)** | **n** | **Number of events** | **Event rate (%/year)** | **HR (95% CI)** |
| ≥ 30 to ≤ 50 | 1,302 | 96 | 3.91 | 1,305 | 128 | 5.23 | 0.75 (0.58, 0.98) |
| > 50 to ≤ 70 | 2,093 | 148 | 3.31 | 2,106 | 171 | 3.77 | 0.88 (0.71, 1.10) |
| > 70 to ≤ 90 | 1,661 | 108 | 2.88 | 1,703 | 119 | 3.08 | 0.93 (0.72, 1.21) |
| > 90 to ≤ 110 | 927 | 29 | 1.33 | 960 | 56 | 2.48 | 0.54 (0.34, 0.84) |
| > 110 to ≤ 130 | 497 | 20 | 1.70 | 469 | 24 | 2.14 | 0.79 (0.44, 1.42) |
| > 130 | 462 | 13 | 1.18 | 418 | 21 | 2.08 | 0.58 (0.29, 1.15) |

**Table 8: Number of fatal bleeding events by CrCl category in ENGAGE AF-TIMI 48, safety analysis on-treatmenta**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **CrCl subgroup (mL/min)** | **Edoxaban 60 mg**  **(N = 7,012)** | | | **Warfarin**  **(N = 7,012)** | | |  |
| **n** | **Number of events** | **Event rate (%/year)** | **n** | **Number of events** | **Event rate (%/year)** | **HR (95% CI)** |
| ≥ 30 to ≤ 50 | 1,302 | 9 | 0.36 | 1,305 | 18 | 0.72 | 0.51 (0.23, 1.14) |
| > 50 to ≤ 70 | 2,093 | 8 | 0.18 | 2,106 | 23 | 0.50 | 0.35 (0.16, 0.79) |
| > 70 to ≤ 90 | 1,661 | 10 | 0.26 | 1,703 | 9 | 0.23 | 1.14 (0.46, 2.82) |
| > 90 to ≤ 110 | 927 | 2 | 0.09 | 960 | 3 | 0.13 | --\* |
| > 110 to ≤ 130 | 497 | 1 | 0.08 | 469 | 5 | 0.44 | --\* |
| > 130 | 462 | 2 | 0.18 | 418 | 0 | 0.00 | --\* |

**Table 9: Number of intracranial bleeding events by CrCl category in ENGAGE AF-TIMI 48, safety analysis on-treatmenta**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **CrCl subgroup (mL/min)** | **Edoxaban 60 mg**  **(N = 7,012)** | | | **Warfarin**  **(N = 7,012)** | | |  |
| **n** | **Number of events** | **Event rate**  **(%/year)** | **n** | **Number of events** | **Event rate (%/year)** | **HR (95% CI)** |
| ≥ 30 to ≤ 50 | 1,302 | 16 | 0.64 | 1,305 | 35 | 1.40 | 0.45 (0.25, 0.81) |
| > 50 to ≤ 70 | 2,093 | 19 | 0.42 | 2,106 | 51 | 1.10 | 0.38 (0.22, 0.64) |
| > 70 to ≤ 90 | 1,661 | 17 | 0.44 | 1,703 | 35 | 0.89 | 0.50 (0.28, 0.89) |
| > 90 to ≤ 110 | 927 | 5 | 0.23 | 960 | 6 | 0.26 | 0.87 (0.27, 2.86) |
| > 110 to ≤ 130 | 497 | 2 | 0.17 | 469 | 3 | 0.26 | --\* |
| > 130 | 462 | 1 | 0.09 | 418 | 1 | 0.10 | --\* |

Abbreviations: N = number of subjects in mITT population overall study period; mITT = modified intent to treat; n = number of patients in subgroup; HR = hazard ratio versus warfarin;

CI = confidence interval.

\*HR not computed if number of events < 5 in one treatment group.

a On-Treatment: Time from first dose of study medicinal product to last dose plus 3 days.

In subgroup analyses, for subjects in the 60 mg treatment group who were dose reduced to 30 mg in the ENGAGE AF-TIMI 48 study for body weight ≤ 60 kg, moderate renal impairment, or concomitant use of P-gp inhibitors, 104 (3.05% per year) of edoxaban 30 mg dose reduced subjects and 166 (4.85% per year) of warfarin dose reduced subjects had a major bleeding event [HR (95% CI): 0.63 (0.50, 0.81)].

In the ENGAGE AF-TIMI 48 study there was a significant improvement in net clinical outcome (first stroke, SEE, major bleed, or all-cause mortality; mITT population, overall study period) in favour of edoxaban, HR (95% CI): 0.89 (0.83, 0.96); p = 0.0024, when edoxaban 60 mg treatment group was compared to warfarin.

*Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE)*

The edoxaban clinical programme for VTE was designed to demonstrate the efficacy and safety of edoxaban in the treatment of DVT and PE, and the prevention of recurrent DVT and PE.

In the pivotal Hokusai-VTE study, 8,292 subjects were randomised to receive initial heparin therapy (enoxaparin or unfractionated heparin) followed by edoxaban 60 mg once daily or the comparator. In the comparator arm, subjects received initial heparin therapy concurrently with warfarin, titrated to a target INR of 2.0 to 3.0, followed by warfarin alone. The treatment duration was from 3 months up to 12 months, determined by the investigator based on the patient’s clinical features.

The majority of edoxaban treated patients were Caucasians (69.6%) and Asians (21.0%); 3.8% were Black, and 5.3% were categorised as Other race.

The duration of therapy was at least 3 months for 3,718 (91.6%) edoxaban subjects versus 3,727 (91.4%) of warfarin subjects; at least 6 months for 3,495 (86.1%) of edoxaban subjects versus 3,491 (85.6%) of warfarin subjects; and 12 months for 1,643 (40.5%) edoxaban subjects versus 1,659 (40.4%) of warfarin subjects.

The primary efficacy endpoint was the recurrence of symptomatic VTE, defined as the composite of recurrent symptomatic DVT, non-fatal symptomatic PE and fatal PE in subjects during the 12-month study period. Secondary efficacy outcomes included the composite clinical outcome of recurrent VTE and all-cause mortality.

Edoxaban 30 mg once daily was used for subjects with one or more of the following clinical factors: moderate renal impairment (CrCl 30 - 50 mL/min); body weight ≤ 60 kg; concomitant use of specific P-gp inhibitors.

In the Hokusai-VTE study (Table 10) edoxaban was demonstrated to be non-inferior to warfarin for the primary efficacy outcome, recurrent VTE, which occurred in 130 of 4,118 subjects (3.2%) in the edoxaban group versus 146 of 4,122 subjects (3.5%) in the warfarin group [HR (95% CI): 0.89 (0.70, 1.13); p < 0.0001 for non-inferiority]. In the warfarin group, the median TTR (INR 2.0 to 3.0) was 65.6%. For subjects presenting with PE (with or without DVT), 47 (2.8%) of edoxaban and 65 (3.9%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.73 (0.50, 1.06)].

## Table 10: Efficacy results from the Hokusai-VTE study - mITT population, overall study period

|  |  |  |  |
| --- | --- | --- | --- |
| **Primary endpointa** | **Edoxaban 60 mg (30 mg dose reduced)**  **(N = 4,118)** | **Warfarin (N = 4,122)** | **Edoxaban vs Warfarin**  **HR (95% CI)b**  **p-valuec** |
| All subjects with symptomatic recurrent VTE**c**, n (%) | 130 (3.2) | 146 (3.5) | 0.89 (0.70, 1.13)  p-value < 0.0001 (non-inferiority) |
| PE with or without DVT | 73 (1.8) | 83 (2.0) |  |
| Fatal PE or death where PE cannot be ruled out | 24 (0.6) | 24 (0.6) |  |
| Non-fatal PE | 49 (1.2) | 59 (1.4) |  |
| DVT only | 57 (1.4) | 63 (1.5) |  |

Abbreviations: CI = confidence interval; DVT = deep vein thrombosis; mITT = modified intent-to- treat; HR = Hazard ratio vs. warfarin; n = number of subjects with events; N = number of subjects in mITT population; PE = pulmonary embolism; VTE = venous thromboembolic events.

a The primary efficacy endpoint is adjudicated symptomatic recurrent VTE (i.e., the composite endpoint of DVT, non-fatal PE, and fatal PE).

b The HR, two-sided CI are based on the Cox proportional hazards regression model including treatment and the following randomisation stratification factors as covariates: presenting diagnosis (PE with or without DVT, DVT only), baseline risk factors (temporary factors, all others), and the need for 30 mg edoxaban/edoxaban placebo dose at randomisation (yes/no).

c The p-value is for the pre-defined non-inferiority margin of 1.5.

For the subjects who were dose reduced to 30 mg (predominantly low body weight or renal function) 15 (2.1%) edoxaban and 22 (3.1%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.69 (0.36, 1.34)].

The secondary composite endpoint of recurrent VTE and all-cause mortality occurred in 138 subjects (3.4%) in the edoxaban group and 158 subjects (3.9%) in the warfarin group [HR (95% CI): 0.87 (0.70, 1.10)].

The results for all-cause mortality (adjudicated deaths) in Hokusai-VTE were 136 (3.3%) for subjects taking edoxaban 60 mg (30 mg dose reduced) as opposed to 130 (3.2%) for warfarin.

In a pre-specified subgroup analysis of PE subjects 447 (30.6%) and 483 (32.2%) of edoxaban and warfarin treated subjects, respectively, were identified as having PE and N-terminal pro–B-type natriuretic peptide (NT-proBNP) ≥ 500 pg/mL. The primary efficacy outcome occurred in 14 (3.1%) and 30 (6.2%) of edoxaban and warfarin subjects, respectively [HR (95% CI): 0.50 (0.26, 0.94)].

The efficacy results for pre-specified major subgroups (with dose reduction as required), including age, body weight, gender and status of renal function were consistent with the primary efficacy results for the overall population studied in the trial.

The primary safety endpoint was clinically relevant bleeding (major or clinically relevant non-major).

Table 11 summarises adjudicated bleeding events for the safety analysis set on-treatment period.

There was a significant risk reduction in the edoxaban group compared with warfarin for the primary safety endpoint of clinically relevant bleeding, a composite of major bleeding or clinically relevant non-major (CRNM) bleeding, which occurred in 349 of 4,118 subjects (8.5%) in the edoxaban group and in 423 of 4,122 subjects (10.3%) in the warfarin group [HR (95% CI): 0.81 (0.71, 0.94); p = 0.004 for superiority].

## Table 11: Bleeding events in Hokusai-VTE study - safety analysis on-treatment perioda

|  |  |  |
| --- | --- | --- |
|  | **Edoxaban 60 mg (30 mg dose reduced)**  **(N = 4,118)** | **Warfarin**  **(N = 4,122)** |
| **Clinically relevant bleeding**  (Major and CRNM)**b**, n (%) |  |  |
| n | 349 (8.5) | 423 (10.3) |
| HR (95% CI) | 0.81 (0.71, 0.94) |  |
| p-value | 0.004 (for superiority) |  |
| **Major bleeding** n (%) |  |  |
| n | 56 (1.4) | 66 (1.6) |
| HR (95% CI) | 0.84 (0.59, 1.21) |  |
| ICH fatal | 0 | 6 (0.1) |
| ICH non-fatal | 5 (0.1) | 12 (0.3) |
| **CRNM bleeding** |  |  |
| n | 298 (7.2) | 368 (8.9) |
| HR (95% CI) | 0.80 (0.68, 0.93) |  |
| **All bleeding** |  |  |
| n | 895 (21.7) | 1,056 (25.6) |
| HR (95% CI) | 0.82 (0.75, 0.90) |  |

Abbreviations: ICH = intracranial haemorrhage, HR = hazard ratio vs. warfarin; CI = confidence interval; N = number of subjects in safety population; n = number of events; CRNM = clinically relevant non-major

a On-treatment period: time from first dose of study medicinal product to last dose plus 3 days.

b Primary safety endpoint: clinically relevant bleeding (composite of major and clinically relevant non-major bleeding).

In subgroup analyses, for subjects who were dose reduced to 30 mg in the Hokusai-VTE study for body weight ≤ 60 kg, moderate renal impairment, or concomitant use of P-gp inhibitors, 58 (7.9%) of edoxaban 30 mg dose reduced subjects and 92 (12.8%) of warfarin subjects had a major bleeding or CRNM event [HR (95%): 0.62 (0.44, 0.86)].

In the Hokusai-VTE study the net clinical outcome (recurrent VTE, major bleed, or all-cause mortality; mITT population, overall study period) HR (95% CI) was 1.00 (0.85, 1.18) when edoxaban was compared to warfarin.

*Prevention of stroke and systemic embolism in NVAF patients with high CrCl (CrCl > 100 mL/min)*

A dedicated randomised, double-blind trial (E314) was conducted in 607 NVAF patients with high CrCl (CrCl > 100 mL/min as measured by the Cockcroft-Gault formula) with the primary aim to evaluate the PK/PD of an edoxaban 60 mg once daily vs 75 mg once daily regimen. In addition to the primary PK/PD endpoint, the study included the evaluation of clinical endpoints of stroke and bleeding over a 12-months treatment period.

An edoxaban dose of 75 mg QD in the high CrCl sub-group (> 100 mL/min) provided an ~25% increase in exposure as compared to an edoxaban dose of 60 mg QD as predicted.

The number of subjects experiencing the adjudicated composite endpoint of stroke/transient ischaemic attack (TIA)/systemic embolic event (SEE) efficacy events was limited and included 2 stroke events in the edoxaban 60 mg group (0.7%; 95% CI: 0.1% to 2.4%) and 3 stroke events in the edoxaban 75 mg group (1%; 95% CI: 0.2% to 2.9%).

Adjudicated major bleeding events occurred in 2 (0.7%; 95% CI: 0.1% to 2.4%) subjects in the edoxaban 60 mg group compared to 3 (1.0%; 95% CI: 0.2% to 2.9%) subjects in the edoxaban 75 mg group. Of the 2 major bleeds in the edoxaban 60 mg group, one was in a critical area/organ (intraocular) and the other major bleed was an intramuscular bleed. Of the 3 major bleeds in the edoxaban 75 mg group, 2 occurred in a critical area/organ (intracerebral/ 1 fatal outcome) and 1 was an upper gastrointestinal (GI) bleed (life-threatening). There were also 9 (3%) clinically relevant non- major (CRNM) bleedings in the edoxaban 60 mg group and 7 (2.3%) CRNM bleedings in the edoxaban 75 mg group.

In addition to the E314 clinical trial, a prospective, multinational, multi-centre, post authorisation, observational study (ETNA-AF) was conducted in 10 European countries and has included 13,980 subjects. Within this population 1,826 had a CrCl > 100 ml/min and received edoxaban 60 mg in accordance with dosing criteria outlined in the SmPC. The annual rates of the composite of ischaemic stroke or systemic embolism were 0.39%/y, and major bleeding events occurred in 0.73%/y.

Given the totality of the data from ENGAGE AF, E314 and ETNA-AF, patients with NVAF and high CrCl treated with edoxaban 60 mg are expected to have an annual rate of ischaemic stroke/systemic embolism ≤ 1%. Increasing the dose above 60 mg in NVAF patients with high CrCl (> 100 mL/min) is not expected to provide more protection against stroke and can be associated with increased adverse events. As such, an edoxaban 60 mg once daily regimen is recommended in these patients after a careful evaluation of the individual thromboembolic and bleeding risk (see section 4.4.).

*Patients undergoing cardioversion*

A multicentre, prospective, randomised, open-label study with blinded endpoint evaluation (ENSURE- AF) was conducted which randomised 2199 subjects (oral anticoagulant naïve and pre-treated) with NVAF scheduled for cardioversion, to compare edoxaban 60 mg once daily with enoxaparin/warfarin to maintain a therapeutic INR of 2.0 to 3.0 (randomised 1:1), mean TTR on warfarin was 70.8%. A total of 2149 subjects were treated with either edoxaban (N = 1067) or enoxaparin/warfarin (N = 1082). Subjects in the edoxaban treatment group received 30 mg once daily if one or more of the following clinical factors were present: moderate renal impairment (CrCl 30 – 50 mL/min), low body weight (≤ 60 kg) or concomitant use of specific P-gp inhibitors. The majority of subjects in the edoxaban and warfarin groups had cardioversion performed (83.7% and 78.9%, respectively) or were auto-converted (6.6% and 8.6%, respectively). TEE-guided (within 3 days of initiation) or conventional cardioversion (at least 21 days of pre-treatment) was employed. Subjects were maintained on treatment for 28 days post cardioversion.

The primary efficacy outcome consisted of a composite of all stroke, SEE, MI and CV mortality. A total of 5 (0.5%, 95% CI 0.15% - 1.06%) events occurred in subjects in the edoxaban group (N = 1095) and 11 (1.0%, 95% CI 0.50% - 1.78%) events in the warfarin group (N = 1104); odds ratio (OR) 0.46 (95% CI 0.12 - 1.43); ITT analysis set overall study period with mean duration of 66 days.

The primary safety outcome was a composite of major and CRNM bleeding. A total of 16 (1.5%, 95% CI 0.86% - 2.42%) events occurred in subjects in the edoxaban (N = 1067) group and 11 (1.0%, 95% CI 0.51% - 1.81%) events in the warfarin (N = 1082) group; OR 1.48 (95% CI 0.64 - 3.55); safety analysis set on-treatment period.

This exploratory study showed low rates of major and CRNM bleeding and thromboembolism in the two treatment groups in the setting of cardioversion.

Paediatric population

The safety, efficacy, pharmacokinetics and pharmacodynamics of edoxaban in paediatric subjects from birth to 18 years of age with VTE and cardiac diseases at risk of thrombotic events were evaluated in two Phase 3 studies, Hokusai VTE PEDIATRICS and ENNOBLE-ATE (see section 4.2). The pivotal paediatric study, Hokusai VTE PEDIATRICS, is described below.

The pivotal study (Hokusai VTE PEDIATRICS) was a Phase 3, open-label, randomised, multi-centre, controlled study to evaluate the pharmacokinetics and pharmacodynamics of edoxaban and compare the efficacy and safety of edoxaban with standard of care (control group) anticoagulant therapy in paediatric subjects from birth to less than 18 years of age with confirmed venous thromboembolism (VTE).

The primary efficacy endpoint was the composite endpoint of symptomatic recurrent venous thromboembolic disease, death as result of VTE, and no change or extension of thrombotic burden during the first 3-month period (intended duration of treatment was 6 to 12 weeks for paediatric patients from birth to less than 6 months of age).

The edoxaban doses tested in the Hokusai VTE PEDIATRICS were established according to age and weight. Dose reductions were recommended based on clinical factors, including renal function and concomitant use of P-gp inhibitors (Table 12).

**Table 12: Edoxaban dose tested in the Hokusai VTE PEDIATRICS study**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Age at Date of Consent** | **Body Weight** | **Dose (Tablet)a** | **Dose (Suspension)a** | **Dose Reductionb** |
| 12 to <18 yrs. | ≥60 kg | 60 mg | NA | 45 mg |
| ≥30 and <60 kg | 45 mg | NA | 30 mg |
| <5th percentile for age | 30 mg | NA | NA |
| 6 to <12 yrs. | <60 kg; dosed based on mg/kg | NA | 1.2 mg/kg  (maximum 45 mg) | 0.8 mg/kg  (maximum 45 mg) |
| 2 to <6 yrs. | Dosed based on mg/kg | NA | 1.4 mg/kg  (maximum 45 mg) | 0.7 mg/kg  (maximum: 24 mg) |
| 6 months to <2 yrs. | Dosed based on mg/kg | NA | 1.5 mg/kg  (maximum 45 mg) | 0.75 mg/kg  (maximum: 24 mg) |
| >28 days to <6 months | Dosed based on mg/kg | NA | 0.8 mg/kg  (maximum 12 mg) | 0.4 mg/kg  (maximum 6 mg) |
| Birth (38 weeks of gestation) to ≤28 days | Dosed based on mg/kg | NA | 0.4 mg/kg  (maximum 6 mg) | 0.4 mg/kg  (maximum 6 mg) |

NA = not applicable; yrs. = years

a Subjects were instructed to take edoxaban (tablets or granules) orally once a day, at the same time every day, with or without food. Tablets were to be swallowed with a glass of water.

b based on clinical factors, including renal function (moderate-severe renal impairment with estimated glomerular filtration rate (eGFR) 10-20, 20-35, 30-50 mL/min/1.73m2 for subjects aged >4 and ≤8 weeks, >8 weeks and ≤2 years, >2 and ≤12 years; eGFR 35-55 mL/min/1.73m2 for boys >12 and <18 years; and eGFR 30-50 mL/min/1.73m2 for girls >12 and <18 years) and concomitant use of P-gp inhibitors (e.g.: ciclosporin, dronedarone, erythromycin, ketoconazole).

A total of 290 subjects were randomised into the study: 147 in the edoxaban group and 143 in the standard of care control group, of which 286 subjects took at least one dose of study medication (mITT); 145 subjects in the edoxaban group and 141 subjects in the control group. Approximately half of the overall subjects were male (52.4%) and the majority of subjects treated were white (177 [61.9%] subjects). The mean weight was 45.35 kg and the mean BMI was 20.4 kg/m2. In total, 167 (58.4%) subjects were in the 12 to <18 years cohort, 44 (15.4%) subjects were in the 6 to <12 years cohort, 31 (10.8%) subjects were in the 2 to <6 years cohort, 28 (9.8%) subjects were in the 6 months to <2 years cohort, and 16 (5.6%) subjects were in the 0 to <6 months cohort. A total of, 28 (19.3%) children in the edoxaban group and 31 (22.0%) children in the control group had a medical history of neoplasms. The type of index event was DVT with or without PE in 125 (86.2%) of 145 children of the edoxaban group and 121 (85.8%) of 141 children in the control group, while the remaining cases, 20 (13.8%) in the edoxaban group and 20 (14.2%) in the control group were PE without DVT. DVTs were most frequently localized in the lower extremities (50 (34.5%) and 44 (31.2%) cases in the edoxaban and control groups, respectively), upper extremities (22 (15.2%) vs 24 (17.0%)), and cerebral venous sinus (27 (18.6%) vs. 21 (14.9%)).

The HR for the edoxaban group versus the standard of care control group was 1.01 (95% CI: 0.59 to 1.72). The upper bound of the 95% CI (1.72) exceeded the predefined non-inferiority margin of 1.5, hence the non-inferiority of edoxaban versus standard of care was not confirmed (see Table 13).

**Table 13: Adjudicated Composite Primary Efficacy Endpoint – Main Treatment Period (mITT Analysis Set)**

|  |  |  |
| --- | --- | --- |
|  | **Edoxaban**  **(N = 145)** | **Standard of care**  **(N = 141)** |
| Subjects with events (n, %) | 26 (17.9) | 31 (22.0) |
| Symptomatic recurrent VTE (n, %) | 5 (3.4) | 2 (1.4) |
| PE with or without DVT (n, %) | 0 | 1 (0.7) |
| Fatal PE (n, %) | 0 |  |
| Nonfatal PE (n, %) | 0 | 1(0.7) |
| DVT only (n, %) | 5 (3.4) | 1 (0.7) |
| Fatal DVT (n, %) | 0 | 0 |
| Nonfatal DVT (n, %) | 4 (2.8) | 0 |
| Unexplained death which VTE cannot be ruled out (n, %) | 1 (0.7) | 1 (0.7) |
| No change or extension of thrombotic burden based on imaging (n, %) | 21 (14.5) | 29 (20.6) |
| Hazard ratioa | 1.01 | - |
| 2-sided 95% CI for hazard ratio | (0.59, 1.72) | - |

CI = confidence interval; DVT = deep vein thrombosis; mITT = Modified Intent-to-Treat; PE = pulmonary embolism; VTE = venous thromboembolism.

a Edoxaban-to-standard of care hazard ratio.

Note: Adjudicated composite primary efficacy endpoint includes symptomatic recurrent VTE, death as a result of VTE, and no change or extension of thrombotic burden based on imaging.

Note: Main Treatment Period is defined as from randomization to Month 3 Visit + 3 days.

The primary safety endpoint was a combination of major and CRNM bleeding events, occurring during the Main Treatment Period (3 months + 3 days).

The safety results were comparable between the edoxaban and standard of care control groups. A total of 3 (2.1%) subjects in the edoxaban group and 5 (3.5%) subjects in the control group experienced at least 1 adjudicated confirmed major and CRNM bleeding event during the Main Treatment Period and On-Treatment [HR (95% CI): 0.60 (0.139, 2.597)].

**5.2 Pharmacokinetic properties**

Absorption

Edoxaban is absorbed with peak plasma concentrations within 1 - 2 hours following oral administration of edoxaban tablets. The absolute bioavailability is approximately 62%. Food increases peak exposure of edoxaban tablets to a varying extent, but has minimal effect on total exposure. Edoxaban was administered with or without food in the ENGAGE AF-TIMI 48 and the Hokusai-VTE studies as well as paediatric efficacy and safety studies. Edoxaban is poorly soluble at pH of 6.0 or higher. Co-administration of proton-pump inhibitors had no relevant impact on edoxaban exposure.

In a study with 30 healthy subjects, both mean AUC and Cmax values for 60 mg edoxaban administered as a crushed tablet orally mixed in apple puree or via nasogastric tube suspended in water were bioequivalent to the intact tablet. Given the predictable, dose-proportional pharmacokinetic profile of edoxaban, the bioavailability results from this study are likely applicable to lower edoxaban doses.

Distribution

Disposition is biphasic. The volume of distribution is 107 (19.9) L mean (SD).

*In vitro* plasma protein binding is approximately 55%. There is no clinically relevant accumulation of edoxaban (accumulation ratio 1.14) with once daily dosing. Steady state concentrations are achieved within 3 days.

Biotransformation

Unchanged edoxaban is the predominant form in plasma. Edoxaban is metabolised via hydrolysis (mediated by carboxylesterase 1), conjugation or oxidation by CYP3A4/5 (< 10%). Edoxaban has three active metabolites, the predominant metabolite (M-4), formed by hydrolysis, is active and reaches less than 10% of the exposure of the parent compound in healthy subjects. Exposure to the other metabolites is less than 5%. Edoxaban is a substrate for the efflux transporter P-gp, but not a substrate for uptake transporters such as organic anion transporter polypeptide OATP1B1, organic anion transporters OAT1 or OAT3 or organic cation transporter OCT2. Its active metabolite is a substrate for OATP1B1.

Elimination

In healthy subjects, the total clearance is estimated as 22 (± 3) L/hour; 50% is renally cleared (11 L/hour). Renal clearance accounts for approximately 35% of the administered dose. Metabolism and biliary/intestinal excretion account for the remaining clearance. The t½ for oral administration is 10 - 14 hours.

Linearity/non-linearity

Edoxaban displays approximately dose-proportional pharmacokinetics for doses of 15 mg to 60 mg in healthy subjects.

Special populations

*Elderly*

After taking renal function and body weight into account, age had no additional clinically significant effect on edoxaban pharmacokinetics in a population pharmacokinetic analysis of the pivotal Phase 3 study in NVAF (ENGAGE AF-TIMI 48).

*Renal impairment*

The plasma AUCs for subjects with mild (CrCl > 50 - 80 mL/min), moderate (CrCl 30 – 50 mL/min) and severe (CrCl < 30 mL/min but not undergoing dialysis) renal impairment were increased by 32%, 74%, and 72%, respectively, relative to subjects with normal renal function. In patients with renal impairment the metabolite profile changes and a higher quantity of active metabolites are formed.

There is a linear correlation between edoxaban plasma concentration and anti-FXa activity regardless of renal function.

Subjects with ESRD undergoing peritoneal dialysis had 93% higher total exposure compared with healthy subjects.

Population PK modeling indicates that exposure approximately doubles in patients with severe renal impairment (CrCl 15 – 29 mL/min) relative to patients with normal renal function.

Table 14 below shows the edoxaban anti-FXa activity by CrCl category for each indication.

## Table 14: Edoxaban anti-FXa activity by CrCl

|  |  |  |  |
| --- | --- | --- | --- |
| **Edoxaban**  **dose** | **CrCl (mL/min)** | **Edoxaban Anti-FXa activity post-dose (IU/mL)1** | **Edoxaban Anti-FXa activity pre-dose (IU/mL)2** |
|  | Median [2.5 – 97.5% range] | | |
| Prevention of stroke and systemic embolism: NVAF | | | |
| 30 mg once daily | ≥ 30 to ≤ 50 | 2.92 | 0.53 |
|  |  | [0.33 – 5.88] | [0.11 – 2.06] |
| 60 mg once daily \* | > 50 to ≤ 70 | 4.52 | 0.83 |
|  |  | [0.38 – 7.64] | [0.16 – 2.61] |
|  | > 70 to ≤ 90 | 4.12 | 0.68 |
|  |  | [0.19 – 7.55] | [0.05 – 2.33] |
|  | > 90 to ≤ 110 | 3.82 | 0.60 |
|  |  | [0.36 – 7.39] | [0.14 – 3.57] |
|  | > 110 to ≤ 130 | 3.16 | 0.41 |
|  |  | [0.28 – 6.71] | [0.15 – 1.51] |
|  | > 130 | 2.76 | 0.45 |
|  |  | [0.12 – 6.10] | [0.00 – 3.10] |
| Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE) | | | |
| 30 mg once daily | ≥ 30 to ≤ 50 | 2.21 | 0.22 |
|  |  | [0.14 – 4.47] | [0.00 – 1.09] |
| 60 mg once daily \* | > 50 to ≤ 70 | 3.42 | 0.34 |
|  |  | [0.19 – 6.13] | [0.00 – 3.10] |
|  | > 70 to ≤ 90 | 2.97 | 0.24 |
|  |  | [0.24 – 5.82] | [0.00 – 1.77] |
|  | > 90 to ≤ 110 | 2.82 | 0.20 |
|  |  | [0.14 – 5.31] | [0.00 – 2.52] |
|  | > 110 to ≤ 130 | 2.64 | 0.17 |
|  |  | [0.13 – 5.57] | [0.00 – 1.86] |
|  | > 130 | 2.39 | 0.13 |
|  |  | [0.10 – 4.92] | [0.00 – 2.43] |

\* Dose reduction to 30 mg for low body weight ≤ 60 kg or specific concomitant P-gp inhibitors

1 Post-dose is equivalent to Cmax (post-dose samples were drawn 1 – 3 hours after edoxaban administration)

2 Pre-dose is equivalent to Cmin

Although treatment with edoxaban does not require routine monitoring, the effect on anticoagulation can be estimated by a calibrated quantitative anti-FXa assay which may be useful in exceptional situations where knowledge of edoxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see also section 4.4).

A 4 hour haemodialysis session reduced total edoxaban exposures by less than 9%.

*Hepatic impairment*

Patients with mild or moderate hepatic impairment exhibited comparable pharmacokinetics and pharmacodynamics to their matched healthy control group. Edoxaban has not been studied in patients with severe hepatic impairment (see section 4.2).

*Gender*

After accounting for body weight, gender had no additional clinically significant effect on edoxaban pharmacokinetics in a population pharmacokinetic analysis of the Phase 3 study in NVAF (ENGAGE AF-TIMI 48).

*Ethnic origin*

In a population pharmacokinetic analysis of the ENGAGE AF-TIMI 48 study, peak and total exposure in Asian patients and non-Asian patients were comparable.

*Paediatric population*

The pharmacokinetics of edoxaban was evaluated in 208 paediatric subjects across 3 clinical studies (Hokusai VTE PEDIATRICS, ENNOBLE-ATE, and a single-dose PK/PD study) using a population pharmacokinetic (PopPK) model. The pharmacokinetic data of 141 paediatric subjects enrolled in Hokusai VTE PEDIATRICS and ENNOBLE-ATE were included in the PopPK analysis. The exposure of edoxaban in paediatric subjects tended to be within the range of exposures observed in adult patients, but there was a 20-30% underexposure in adolescents aged 12 to <18 years compared to adults who received the edoxaban 60 mg tablets. In Hokusai VTE PEDIATRICS and ENNOBLE-ATE, the observed geometric mean trough exposures of edoxaban in the paediatric population were 7.8 ng/mL in subjects 0 to <6 months of age (N = 9), 8.6 ng/mL in subjects 6 months to <2 years of age (N = 19), 7.4 ng/mL in subjects 2 to <6 years of age (N = 36), 13.7 ng/mL in subjects 6 to <12 years of age (N = 38), and 10.8 ng/mL in subjects 12 to <18 years of age (N = 39).

*Body weight*

In a population pharmacokinetic analysis of the ENGAGE AF-TIMI 48 study in NVAF, Cmax and AUC in patients with median low body weight (55 kg) were increased by 40% and 13%, respectively, as compared with patients with median high body weight (84 kg). In Phase 3 clinical studies (both NVAF and VTE indications) patients with body weight ≤ 60 kg had a 50% edoxaban dose reduction and had similar efficacy and less bleeding when compared to warfarin.

Pharmocokinetic/pharmacodynamic relationship(s)

PT, INR, aPTT and anti-FXa correlate linearly with edoxaban concentrations in adults. A linear correlation was also observed between anti-Fxa activities and the plasma concentrations of edoxaban in paediatric patients from birth to 18 years of age. Overall, the PK-PD relationships were similar between paediatric patients from birth to 18 years of age and adult VTE patients. However, the variability in PD generated considerable uncertainty in the assessment of this relationship.

**5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, or phototoxicity.

Reproductive toxicology

Edoxaban showed vaginal haemorrhage at higher doses in rats and rabbits but had no effects in the reproductive performance of parent rats.

In rats, no effects on male or female fertility were seen.

In animal reproduction studies, rabbits showed increased incidence of gallbladder variations at a dose of 200 mg/kg which is approximately 65 times the maximum recommended human dose (MRHD) of 60 mg/day based on total body surface area in mg/m2. Increased post-implantation pregnancy losses occurred in rats at 300 mg/kg/day (approximately 49 times the MRHD) and in rabbits at 200 mg/kg/day (approximately 65 times the MRHD) respectively.

Edoxaban was excreted in the breast milk of lactating rats.

Environmental risk assessment (ERA)

The active substance edoxaban tosilate monohydrate is persistent in the environment (for instructions on disposal see section 6.6).

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Tablet core:

Hydroxypropylcellulose (E463)

Lactose monohydrate

Magnesium stearate (E470b)

Cellulose, microcrystalline (E460)

Croscarmellose sodium (E468)

Film-coat:

Hypromellose type 2910, 6.0 mPas. (E464)

Macrogol

Titanium dioxide (E171)

Talc (E553b)

*Edoxaban "Sandoz" 30 mg film-coated tablets*

Iron oxide red (E172)

*Edoxaban "Sandoz" 60 mg film-coated tablets*

Iron oxide yellow (E172)

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years.

**6.4 Special precautions for storage**

Store below 25 ºC.

**6.5 Nature and contents of container**

Edoxaban "Sandoz" are packed into PVC/Aluminium blisters, PVC/Aluminium perforated unit dose blisters or HDPE bottles with a polypropylene child resistant screw cap.

Blister pack sizes:

10, 14, 28, 30, 50, 84, 98 and 100 film-coated tablets in blisters in cartons.

10×1, 28×1 and 98×1 film-coated tablets in unit dose blisters in cartons.

Blisters may or may not have imprinted calendar days.

Bottle pack sizes:

100, 120 and 250 film-coated tablets.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Edoxaban "Sandoz" tablets may be crushed and suspended in a small amount of water (60 mL) and immediately delivered through a nasogastric tube or gastric feeding tube (made from silicone, PVC or PU material (gauges equal or larger than 8 FR and length up to 125 cm)) after which it should be flushed with water (60 mL) after delivering the tablet suspension (see section 5.2). Edoxaban "Sandoz" suspension should be administered within 4 hours of preparation. If not used immediately shake the suspension before administration.

**7. MARKETING AUTHORISATION HOLDER**

Sandoz A/S

Edvard Thomsens Vej 14

2300 København S

**8. MARKETING AUTHORISATION NUMBER(S)**

30 mg: 70028

60 mg: 70029

**9. DATE OF FIRST AUTHORISATION**

6 January 2025

**10. DATE OF REVISION OF THE TEXT**

-